ProQR Therapeutics N.V. (PRQR)

ProQR Therapeutics Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	117.13	92.41	149.41	118.93	94.78	187.52
Cash & Short-Term Investments	117.13	92.41	149.41	118.93	94.78	187.52
Cash Growth	-2.20%	-38.15%	25.63%	25.48%	-49.46%	147.27%
Accounts Receivable	3.91	-	-	-	56.25	-
Other Receivables	0.6	5.09	2.03	1.27	0.98	0.82
Receivables	4.51	5.09	2.03	1.27	57.24	0.82
Prepaid Expenses	-	2.63	2.41	0.79	2.45	3.14
Total Current Assets	121.63	100.13	153.85	120.99	154.46	191.48
Property, Plant & Equipment	11.92	12.63	14.11	16.9	16.24	17.47
Long-Term Investments	-	-	-	-	0.62	0.63
Total Assets	133.55	112.76	167.96	137.88	171.32	209.58

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	-	0.3	0.02	1.54	0.39	0.19
Accrued Expenses	0.21	-	1.48	1.66	1.12	1.23
Current Portion of Long-Term Debt	-	4.87	4.58	-	2.5	4.77
Current Portion of Leases	1.6	1.55	1.57	1.61	1.39	1.53
Current Unearned Revenue	17.64	17.55	21.94	20.57	5.64	5.12
Other Current Liabilities	10.4	8.17	9.32	8.82	9.95	14.76
Total Current Liabilities	34.87	32.44	38.9	34.2	20.99	27.6
Long-Term Debt	-	-	-	4.29	4.27	39.32
Long-Term Leases	8.69	9.55	11.07	13.83	13.81	14.75
Long-Term Unearned Revenue	10.51	21.39	29.43	44.17	65.57	14.69
Total Liabilities	54.08	63.38	79.4	96.49	104.64	96.35

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	79.48	4.31	4.31	3.37	3.37	3
Additional Paid-In Capital	-	483.88	483.81	412.89	412.54	398.31
Retained Earnings	-	-467.51	-427.16	-400.85	-379.11	-317.77
Comprehensive Income & Other	-	28.69	27.6	25.98	30.26	30.3
Total Common Equity	79.48	49.37	88.56	41.39	67.07	113.83
Minority Interest	-	-	-	-	-0.38	-0.6
Shareholders' Equity	79.48	49.37	88.56	41.39	66.68	113.23
Total Liabilities & Equity	133.55	112.76	167.96	137.88	171.32	209.58

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	15.31	15.96	17.22	19.73	21.97	60.37
Net Cash (Debt)	101.81	76.45	132.19	99.19	72.8	127.15
Net Cash Growth	-1.06%	-42.17%	33.27%	36.24%	-42.74%	205.94%
Net Cash Per Share	0.96	0.73	1.54	1.22	1.02	1.98
Filing Date Shares Outstanding	109.96	105.36	105.21	81.35	80.82	71.29
Total Common Shares Outstanding	109.96	105.36	105.21	81.35	80.82	71.29
Working Capital	86.76	67.69	114.94	86.78	133.47	163.89
Book Value Per Share	0.72	0.47	0.84	0.51	0.83	1.60
Tangible Book Value	79.48	49.37	88.56	41.39	67.07	113.83
Tangible Book Value Per Share	0.72	0.47	0.84	0.51	0.83	1.60
Buildings	-	24.19	23.79	24.78	22.86	22.23
Machinery	-	7.53	6.82	5.91	4.91	4.25

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: May 12, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 17, 2026

Data Sources Report a data error